Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis

Completed · Not applicable

Conditions studied: Cystic Fibrosis

In brief

OBJECTIVES: I. Determine the optimum dose of tauroursodeoxycholic acid (TUDCA) required to achieve maximal bioavailability for patients with cystic fibrosis-associated liver disease. II. Compare optimized doses of TUDCA with ursodiol (ursodeoxycholic acid; UDCA) for effects on biliary bile acid composition and metabolism, serum biochemistries, fat absorption, and fat-soluble vitamin status in these patients.

Key facts

Study ID

NCT00004441

Run by

Children's Hospital Medical Center, Cincinnati

People needed

39

Starts

1997-09-01

Expected to finish

2001-09-01

Last updated by the study team

2015-03-25

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Children's Hospital of Denver — Denver, Colorado, United States
• Children's Hospital Medical Center - Cincinnati — Cincinnati, Ohio, United States
• University of Milan — Milan, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.